MBX Biosciences Balance Sheet
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences financial position
At the end of fiscal 2025, MBX Biosciences reported total assets of $385.1 million, up 43.4% from a year earlier against total liabilities of $15.9 million. Shareholders' equity stood at $369.2 million, or 95.9% of assets. The company held $75.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 24.62, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 75.29M | 49.35M | 30.52M |
| Short-Term Investments | 298.42M | 212.80M | 50.15M |
| Total Current Assets | 381.54M | 267.29M | 83.47M |
| Property, Plant & Equipment | 2.73M | 1.08M | 439.00K |
| Total Assets | 385.14M | 268.54M | 84.18M |
| Accounts Payable | 2.98M | 5.33M | 1.39M |
| Total Current Liabilities | 15.49M | 11.05M | 3.93M |
| Total Liabilities | 15.92M | 11.09M | 4.29M |
| Shareholders' Equity | 369.22M | 257.44M | -72.47M |
| Retained Earnings | -224.48M | -137.50M | -75.58M |
| Net Cash (Debt) | 373.70M | 262.15M | 80.68M |
| Shares Outstanding | 44.93M | 33.42M | 1.26M |
This table shows 3 annual periods of MBX Biosciences's balance sheet, from FY 2025 back to FY 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a balance sheet?